OpGen said it intends to use the proceeds of the offering to complete its acquisition of German molecular diagnostics firm Curetis, among other things.
The drug is now approved as a fourth-line option for advanced, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.
The nonpartisan federal agency's report suggests ways for Congress, the FDA, FTC, and CMS to expand oversight of the genetic testing market.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
Inqaba will distribute DNAStar's Lasergene software suite for DNA, RNA, and protein sequence analysis in Africa.
The researchers estimated that addition of RNA-based testing could benefit about 1 in 43 individuals undergoing hereditary cancer predisposition genetic testing.
The grant will fund development of methods using the company's IsoLight system to study protein signaling pathways in single tumor cells.
Although normal tissues with somatic mutations did not necessarily progress to cancer, researchers saw a jump in mutational burden in samples associated with cancer or cirrhosis.
Tumor genomes from almost 2,400 patients with metastatic cancer revealed a range of somatic alterations, providing a foundation for clinical sequencing efforts.
The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.
The company's SpliceCore platform maps patient RNA sequencing data to a collection of over 5 million alternative splicing errors to pinpoint ones that cause disease.
For the three months ended Sept. 30, the firm reported total revenues of $31.0 million, beating analysts' average estimate of $30.1 million.
The collaborators hope to establish new models of human disease using patient-derived stem cells, with support from Bloomberg Philanthropies.
The firm saw 26 percent growth in molecular biology sales, driven in part by 25 percent sales growth for the BioFire FilmArray product line.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
The test is the latest in a series of CE-IVD-marked assays the company has launched for use on Becton Dickinson's PCR-based BD Max platform.
The company has used a portion of the new facility to pay back existing debt to the bank, as well as a final payment designated in the parties' earlier loan agreement.
10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.
Researchers have tied nearly 200 candidate genes, including ones involved in neurodevelopment, apoptosis, and inflammation, to the volume of brain structures.
The Genomics Research and Innovation Network has built an open-source system for querying genotype-phenotype databases at its member hospitals.
Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares.
The sale is being made to obtain regulatory approval of Danaher's pending $21.4 billion acquisition of the GE Biopharma business.
New Horizon Health's test, ColoClear, is a stool-based DNA test specifically designed to detect colon cancer in individuals of Asian descent.
Under the 10-year deal, SomaLogic will analyze at least 250,000 clinical samples to support Novartis' drug development work and its own test development.
Microba offers a direct-to-consumer service that uses shotgun metagenomics to analyze customers' gut microbiomes and generate a personalized report.
The General Data Protection Regulation has slowed some data sharing with non-European researchers as they find ways to comply with the law, ScienceInsider reports.
A bioethicist from Abertay University uses a utilitarian approach to justify genetically modifying the human germline, the BBC reports.
The US has upgraded its network of public health labs to provide whole-genome sequencing to track antibiotic-resistant bacteria, Quartz reports.
In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings, and more.